Henry Schein, Inc. (NASDAQ:HSIC) Director Paul Brons sold 1,758 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $69.34, for a total transaction of $121,899.72. Following the completion of the transaction, the director now owns 15,824 shares in the company, valued at approximately $1,097,236.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of NASDAQ:HSIC opened at $68.91 on Friday. The company has a market capitalization of $10.04 billion, a price-to-earnings ratio of 16.69, a price-to-earnings-growth ratio of 2.62 and a beta of 0.85. The company has a 50 day moving average of $63.16 and a two-hundred day moving average of $65.35. The company has a quick ratio of 0.95, a current ratio of 1.63 and a debt-to-equity ratio of 0.30. Henry Schein, Inc. has a 52-week low of $56.58 and a 52-week high of $72.81.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04. The firm had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.52 billion. Henry Schein had a net margin of 4.66% and a return on equity of 15.93%. The firm’s revenue was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.03 earnings per share. On average, equities analysts anticipate that Henry Schein, Inc. will post 3.45 earnings per share for the current year.
Several research firms recently commented on HSIC. Cleveland Research restated a “hold” rating on shares of Henry Schein in a report on Friday, November 1st. Zacks Investment Research lowered shares of Henry Schein from a “hold” rating to a “sell” rating and set a $71.00 price target on the stock. in a report on Wednesday. BidaskClub lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a report on Thursday, September 26th. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b” rating in a report on Monday, October 14th. Finally, William Blair lowered shares of Henry Schein from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 7th. Six investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $73.50.
A number of institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its holdings in Henry Schein by 12,246.2% in the third quarter. Tower Research Capital LLC TRC now owns 3,210 shares of the company’s stock worth $204,000 after purchasing an additional 3,184 shares during the period. Reilly Herbert Faulkner III boosted its holdings in Henry Schein by 1.7% in the third quarter. Reilly Herbert Faulkner III now owns 74,651 shares of the company’s stock worth $4,740,000 after purchasing an additional 1,268 shares during the period. Daiwa Securities Group Inc. boosted its holdings in Henry Schein by 25.5% in the third quarter. Daiwa Securities Group Inc. now owns 6,801 shares of the company’s stock worth $432,000 after purchasing an additional 1,380 shares during the period. Symmetry Partners LLC acquired a new position in Henry Schein in the third quarter worth $491,000. Finally, Congress Asset Management Co. MA lifted its stake in Henry Schein by 2.9% in the third quarter. Congress Asset Management Co. MA now owns 78,328 shares of the company’s stock valued at $4,974,000 after buying an additional 2,189 shares during the last quarter.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More: Institutional Investors
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.